Ledenfrog, I also agree that Rvx not having a Nasdaq listing has been a major impedement to the U.S. And int'l markets and is most likely the reason why are share price is sitting around $2 to 2.25 . There most likely many U.S. Investor who are so close to pulling the trigger on investing in Rvx. I can only imagine our share price would be significantly higher if we were on the Nasdaq. That being said I wonder if the management is looking at doing a listing or an iPo on the Nasdaq assuming the proper qualifications are in place. For those who have been invested in Rvx for quite some time might remember 2007 where went from $2 to 29 in less than 6 weeks on the tsx . I think if the science is duplicated for the mace results in the phase 3 trial we will see a very quick climb in a very short period of time without the need for a U.S. Listing. Looking forward to the next 6 months,